Dioscin has been demonstrated to enhance the interaction between Skp2 and Cdh1, promoting Skp2 ubiquitination and degradation, and finally decreasing glucose consumption and lactate production in vitro, while treatment with Dioscin has also been shown to inhibit CRC tumor growth in vivo. Here, SKP2 is linked to neoplasm.